These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088 [TBL] [Abstract][Full Text] [Related]
7. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613 [TBL] [Abstract][Full Text] [Related]
8. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Lou JS; Dimitrova DM; Park BS; Johnson SC; Eaton R; Arnold G; Nutt JG Clin Neuropharmacol; 2009; 32(6):305-10. PubMed ID: 19620846 [TBL] [Abstract][Full Text] [Related]
10. Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson's disease. del Olmo MF; Bello O; Cudeiro J Clin Neurophysiol; 2007 Jan; 118(1):131-9. PubMed ID: 17097342 [TBL] [Abstract][Full Text] [Related]
11. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848 [TBL] [Abstract][Full Text] [Related]
12. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH; Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329 [TBL] [Abstract][Full Text] [Related]
13. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Gunzler SA; Koudelka C; Carlson NE; Pavel M; Nutt JG Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187 [TBL] [Abstract][Full Text] [Related]
14. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease. Goberman AM Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562 [TBL] [Abstract][Full Text] [Related]
15. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A; Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922 [TBL] [Abstract][Full Text] [Related]
16. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473 [TBL] [Abstract][Full Text] [Related]
17. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Gordon PH; Yu Q; Qualls C; Winfield H; Dillon S; Greene PE; Fahn S; Breeze RE; Freed CR; Pullman SL Arch Neurol; 2004 Jun; 61(6):858-61. PubMed ID: 15210522 [TBL] [Abstract][Full Text] [Related]